论文部分内容阅读
目的研究根除 Hp 与疗胃煎剂对 Hp 相关 CAG 的治疗作用方法实验研究,90g-110g,二级 Wistar 大鼠70只,随机分为疗胃煎剂治疗组(三种不同剂量)、三九胃泰对照组、单纯根除 Hp 组、自然恢复组与正常组(各10只).采用灌胃接种 SS1Hp 菌株,灌胃水畅酸钠溶液,交替自由饮用50mL/L 乙醇与5 mmool/L 去氧胆酸钠溶液的综合方法制备 Hp 相关 CAG 动物模型.模型制备成功后均先根除 Hp.以三九胃泰为对照进行疗胃煎剂治疗,12 wk 疗程结束后,处死动物进行 Hp 感染,病理组织学检查与粘膜氮基已糖含量检测.临床研究,34例经内镜、病理证实的 Hp 阳性 CAG 患者随机分为疗胃煎剂治疗组和硫糖铝对照组,治疗前后分别进行病理组织学及化验指标检测.结果实验研究结果显示,疗胃煎剂中、高剂量组大鼠粘膜萎缩程度较三九胃泰组,自然恢复组及单纯根除 Hp 组明显减轻[粘膜上皮层厚度(μm)分别为97±14,96±13,73±11,66±12,74±10,P<0.05],中剂量组粘膜氨基己糖增加,与自然恢复组比较(22.53±4.37)mg/g vs(12.21±2.40)mg/gP<0.05.自然恢复组 Hp 均为阳性,粘膜固有层有较明显炎症细胞浸润.其他各实验组 Hp 阴性,粘膜固有层无明显炎症反应.临床研究结果显示,疗胃煎剂对萎缩病变治疗有效率75%(15/20)明显高于硫糖铝组29%(4/14)(P<0.01),粘膜氨基己糖含量增加(41.21±7.73,49.72±12.61,P<0.05).硫糖铝对照组治疗前后无明显变化.结论疗胃煎剂具有增强胃粘膜屏障功能作用,可增加氨基己糖含量,能增加粘膜固有层厚度,是治疗 CAG 的有效药物.
Objective To study the eradication of Hp and treatment of stomach decoction of Hp-related CAG experimental study, 90g-110g, two Wistar rats 70 were randomly divided into treatment of stomach decoction group (three different doses), 39 Weitai control group, simple eradication Hp group, natural recovery group and normal group (each 10) .The intragastric inoculation of SS1Hp strain, gavage sodium hypochlorite solution, alternating freely drinking 50mL / L ethanol and 5mmool / L to go Hox-related CAG animal model was prepared by a comprehensive method of sodium oxonicacid solution.After the successful preparation of the model, Hp was first eradicated.With Sanjiu Weitai as a control, the stomach decoction was treated. After the 12 wk treatment, the animals were sacrificed for Hp infection, Histopathological examination and detection of mucosal nitrogen content of hexose.Clinical study, 34 cases of Hp positive CAG patients confirmed by endoscopy and pathology were randomly divided into treatment of stomach decoction group and control group sucralfate, before and after treatment were pathological Histological and laboratory tests.Results The experimental results showed that the mucosal atrophy in the middle-dose and high-dose groups of Treating Wei decoction was significantly alleviated compared with that of Sanjiuweitai group, natural recovery group and Hp group [thickness of mucosal epithelial layer μm) were 97 ± 14,96 ± 13,73 ± 11,66 ± 12,74 ± 10, P <0.05]. The amount of aminocaproic acid in the mucosa increased in the middle dose group compared with the natural recovery group (22.53 ± 4.37 mg / g vs 12.21 ± 2.40) mg / gP <0.05.Natural recovery group Hp were positive, mucosal lamina propria with more obvious infiltration of inflammatory cells.All the other experimental group Hp negative, mucosa lamina propria no inflammatory reaction.Clinical research results show that the treatment of stomach decoction The effective rate of treatment for atrophic lesions was 75% (15/20), which was significantly higher than that of sucralfate group (29/14) (P <0.01), and the amount of aminocaproic acid in mucosa increased (41.21 ± 7.73,49.72 ± 12.61, P < 0.05) .The sucralfate control group had no significant changes before and after treatment.Conclusion: Weiwei decoction can enhance the barrier function of gastric mucosa, increase the content of hexose hexose and increase the thickness of mucosa lamina propria, which is an effective drug for the treatment of CAG.